Phio Commences Toxicology Study for PH-762, Advances Viable Product in 2026
ByAinvest
Wednesday, Dec 24, 2025 6:37 am ET1min read
PHIO--
Phio Pharmaceuticals has commenced a toxicology study for its lead siRNA compound, PH-762, which is being developed to silence the PD-1 gene in various forms of skin cancer. The company is also advancing initiatives to deliver a commercially viable product in 2026, funded by recent financing. Positive interim safety and efficacy results have been reported in the ongoing Phase 1b trial for PH-762.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet